New perspectives on the biology of acute GVHD

The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have been developed for transplantation in patients who previously would not have been considered HCT candidates. However, its efficacy continued to be limited by the development of frequent and severe acute GVHD. The complex and intricate pathophysiology of acute GVHD is a consequence of interactions between the donor and host innate and adaptive immune responses. Multiple inflammatory molecules and cell types are implicated in the development of GVHD that can be categorized as: (1) triggers that initiate GVHD by therapy-induced tissue damage and the antigen disparities between host and graft tissue; (2) sensors that detect the triggers, that is, process and present alloantigens; (3) mediators such as T-cell subsets (naive, memory, regulatory, Th17 and natural killer T cells) and (4) the effectors and amplifiers that cause damage of the target organs. These multiple inflammatory molecules and cell types that are implicated in the development of GVHD have been described with models that use stepwise cascades. Herein, we provide a novel perspective on the immunobiology of acute GVHD and briefly discuss some of the outstanding questions and limitations of the model systems.

[1]  Billingham Re The biology of graft-versus-host reactions. , 1966 .

[2]  R. Billingham The biology of graft-versus-host reactions. , 1966, Harvey lectures.

[3]  J. Sprent,et al.  Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.

[4]  P. Vassalli,et al.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease , 1987, The Journal of experimental medicine.

[5]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[6]  D. Gilliland,et al.  Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. , 1993, Transplantation.

[7]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[8]  P. Linsley,et al.  In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. , 1994, Blood.

[9]  John S. Thompson,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice , 1994 .

[10]  M. Eckhaus,et al.  Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. , 1994, Blood.

[11]  J. Ferrara,et al.  Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. , 1995, Journal of immunology.

[12]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[13]  F Koning,et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.

[14]  H. V. van Houwelingen,et al.  Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.

[15]  J. Ferrara,et al.  Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. , 1996, Blood.

[16]  J. Crawford,et al.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.

[17]  R. Flavell,et al.  Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.

[18]  A. Nademanee,et al.  Phase III Study Comparing Methotrexate and Tacrolimus ( Prograf , FK 506 ) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation , 1998 .

[19]  M. Sykes,et al.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. , 1998, The Journal of clinical investigation.

[20]  J. Crawford,et al.  Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.

[21]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[22]  J. Ferrara,et al.  Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. , 1998, Transfusion medicine reviews.

[23]  J. Crawford,et al.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. , 1998, The Journal of clinical investigation.

[24]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[25]  D. Taub,et al.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.

[26]  M. Garcia-Ojeda,et al.  Bone Marrow NK1.1− and NK1.1+ T Cells Reciprocally Regulate Acute Graft versus Host Disease , 1999, The Journal of experimental medicine.

[27]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[28]  K. Matsushima,et al.  Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. , 1999, The Journal of clinical investigation.

[29]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[30]  G. Hill,et al.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.

[31]  R. Bronson,et al.  Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. , 2000, The Journal of clinical investigation.

[32]  R. Gress,et al.  Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma , 2000, Leukemia & lymphoma.

[33]  F. P. Nestel,et al.  Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. , 2000, Blood.

[34]  J. Peschon,et al.  Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1 , 2001, The Journal of Immunology.

[35]  R. Negrin,et al.  Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. , 2001, Blood.

[36]  J. Ferrara,et al.  Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis , 2001, The Journal of experimental medicine.

[37]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[38]  S. Chevret,et al.  Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. , 2001, Experimental hematology.

[39]  A. Enk,et al.  Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.

[40]  C. Perreault,et al.  Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease , 2001, Nature Medicine.

[41]  R. Collins,et al.  Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[42]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[43]  D. Thiele,et al.  TNF-TNFR2 Interactions Are Critical for the Development of Intestinal Graft-Versus-Host Disease in MHC Class II-Disparate (C57BL/6J→C57BL/6J × bm12)F1 Mice1 , 2002, The Journal of Immunology.

[44]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[45]  S. Burakoff,et al.  Cytolytic pathways in haematopoietic stem-cell transplantation , 2002, Nature Reviews Immunology.

[46]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[47]  M. Sykes,et al.  Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. , 2002, Blood.

[48]  Eun Young Choi,et al.  Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. , 2002, Immunity.

[49]  J. Crawford,et al.  T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.

[50]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[51]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[52]  S. Clouthier,et al.  Role of CXCR3-induced donor T-cell migration in acute GVHD. , 2003, Experimental hematology.

[53]  P. Reddy Pathophysiology of acute graft‐versus‐host disease , 2003, Hematological oncology.

[54]  Li Zhang,et al.  Inhibition of Graft-Versus-Host Disease by Double-Negative Regulatory T Cells1 , 2003, The Journal of Immunology.

[55]  村田 誠 A human minor histocompatibility antigen resulting from differential expression due to a gene deletion , 2003 .

[56]  L. Appleman,et al.  T cell anergy and costimulation , 2003, Immunological reviews.

[57]  A. Sharpe,et al.  Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. , 2003, Blood.

[58]  G. Núñez,et al.  Cell death and immunity: NODs: intracellular proteins involved in inflammation and apoptosis , 2003, Nature Reviews Immunology.

[59]  J. Ferrara,et al.  Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. , 2003, Blood.

[60]  M. Shlomchik,et al.  Memory CD4+ T cells do not induce graft-versus-host disease. , 2003, The Journal of clinical investigation.

[61]  Stephen C. Jones,et al.  Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[62]  A. Panoskaltsis-Mortari,et al.  Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.

[63]  Irving L Weissman,et al.  Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease , 2004, Nature Medicine.

[64]  J. Serody,et al.  Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning1 , 2004, The Journal of Immunology.

[65]  M. Labopin,et al.  Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  T. Mak,et al.  CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease1 , 2004, The Journal of Immunology.

[67]  G. Rogler,et al.  Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. , 2004, Blood.

[68]  J. Serody,et al.  L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. , 2004, Blood.

[69]  N. Chao,et al.  Transfer of allogeneic CD 62 L memory T cells without graft-versus-host disease , 2004 .

[70]  C. Dinarello,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Riddell,et al.  Molecules and mechanisms of the graft-versus-leukaemia effect , 2004, Nature Reviews Cancer.

[72]  D. Jain,et al.  Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.

[73]  Harriet Noreen,et al.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.

[74]  D. Jain,et al.  Target Antigens Determine Graft-versus-Host Disease Phenotype , 2004, The Journal of Immunology.

[75]  J. Cyster,et al.  Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. , 2005, Annual review of immunology.

[76]  E. Podack,et al.  Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[77]  Matthias Edinger,et al.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.

[78]  B. Bierer,et al.  Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism1 , 2005, The Journal of Immunology.

[79]  J. Ferrara,et al.  Critical role of host γδ T cells in experimental acute graft-versus-host disease , 2005 .

[80]  J. Ferrara,et al.  Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. , 2005, Blood.

[81]  J. Berzofsky,et al.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.

[82]  J. Serody,et al.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. , 2005, Blood.

[83]  M. V. D. van den Brink,et al.  Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. , 2005, Blood.

[84]  J. Serody,et al.  Leukocyte migration and graft-versus-host disease. , 2005, Blood.

[85]  R. Korngold,et al.  A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses , 2005, Nature Medicine.

[86]  Katsuaki Sato,et al.  TRAIL-Transduced Dendritic Cells Protect Mice from Acute Graft-versus-Host Disease and Leukemia Relapse1 , 2005, The Journal of Immunology.

[87]  Jiang Zhu,et al.  Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.

[88]  D. Pellicci,et al.  NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. , 2005, The Journal of clinical investigation.

[89]  K. Kintner,et al.  IL-12-Independent LIGHT Signaling Enhances MHC Class II Disparate CD4+ T Cell Alloproliferation, IFN-γ Responses, and Intestinal Graft-versus-Host Disease1 , 2005, The Journal of Immunology.

[90]  B. Blazar,et al.  Regulatory T cells. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[91]  Jiang Zhu,et al.  Host-reactive CD8+ memory stem cells in graft-versus-host disease , 2005, Nature Medicine.

[92]  G. Hill,et al.  Cytokine Expanded Myeloid Precursors Function as Regulatory Antigen-Presenting Cells and Promote Tolerance through IL-10-Producing Regulatory T Cells1 , 2005, The Journal of Immunology.

[93]  F. Claas,et al.  A Uniform Genomic Minor Histocompatibility Antigen Typing Methodology and Database Designed to Facilitate Clinical Applications , 2006, PloS one.

[94]  M. Malkki,et al.  Genetics of risk factors for graft-versus-host disease. , 2006, Seminars in hematology.

[95]  G. Rogler,et al.  Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. , 2006, Blood.

[96]  O. Boyer,et al.  The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. , 2006, Current Opinion in Immunology.

[97]  Y. Toda,et al.  Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[98]  M. V. D. van den Brink,et al.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.

[99]  Catherine J. Wu,et al.  Induction of tumor immunity following allogeneic stem cell transplantation. , 2006, Advances in immunology.

[100]  R. Bronson,et al.  Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[101]  R. Sackstein A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[102]  E. Holler,et al.  Isolation of CD4+CD25+ regulatory T cells for clinical trials. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[103]  Christopher H Contag,et al.  Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. , 2006, Blood.

[104]  T. Banović,et al.  Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. , 2006, Blood.

[105]  D. Harlan,et al.  T cell–directed therapies: lessons learned and future prospects , 2007, Nature Immunology.

[106]  A. Rudensky,et al.  Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.

[107]  T. George,et al.  Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease1 , 2007, The Journal of Immunology.

[108]  G. Zhu,et al.  treatment of graft-versus-host disease Selective targeting of the LIGHT-HVEM costimulatory system , 2006 .

[109]  W. Murphy,et al.  Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.

[110]  Ruy M Ribeiro,et al.  Determining thymic output quantitatively: using models to interpret experimental T‐cell receptor excision circle (TREC) data , 2007, Immunological reviews.

[111]  Asha B. Pillai,et al.  Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation1 , 2007, The Journal of Immunology.

[112]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[113]  S. McColl,et al.  IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. , 2007, Blood.

[114]  Vincent C. Manganiello,et al.  Foxp3-dependent programme of regulatory T-cell differentiation , 2007, Nature.

[115]  A. Rudensky,et al.  Thymic development and peripheral homeostasis of regulatory T cells. , 2007, Current opinion in immunology.

[116]  J. Wagner,et al.  Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. , 2006, Blood.

[117]  R. Medzhitov Recognition of microorganisms and activation of the immune response , 2007, Nature.

[118]  A. McKenzie,et al.  Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. , 2008, Experimental hematology.

[119]  E. Butcher,et al.  CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease , 2008, Nature Immunology.

[120]  R. Negrin,et al.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. , 2008, Blood.

[121]  D. Jain,et al.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. , 2008, Blood.

[122]  J. Serody,et al.  The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting , 2008, Leukemia & lymphoma.

[123]  S. Akira,et al.  TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. , 2008, Blood.

[124]  R. Korngold,et al.  Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation. , 2008, Blood.

[125]  F. Fallah-Arani,et al.  The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells1 , 2008, The Journal of Immunology.

[126]  M. Bachmann,et al.  The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. , 2008, Blood.

[127]  D. Jain,et al.  Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. , 2008, Blood.

[128]  G. Holländer,et al.  The immunopathology of thymic GVHD , 2008, Seminars in Immunopathology.

[129]  C. Contag,et al.  Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. , 2008, Blood.

[130]  T. Yi,et al.  Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. , 2008, Blood.

[131]  C. Dinarello,et al.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. , 2008, The Journal of clinical investigation.

[132]  Christopher G. King,et al.  IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.

[133]  A. Toubert,et al.  Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. , 2009, Blood.

[134]  A. Palkova,et al.  Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease , 2009, The Journal of experimental medicine.

[135]  Asha B. Pillai,et al.  Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. , 2009, Blood.

[136]  M. Hessner,et al.  Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. , 2009, Blood.

[137]  C. Münz Enhancing immunity through autophagy. , 2009, Annual review of immunology.

[138]  Yang Liu,et al.  CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.

[139]  Michelle L. West,et al.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. , 2009, Blood.

[140]  M. Smyth,et al.  Induction of natural killer T cell–dependent alloreactivity by administration of granulocyte colony–stimulating factor after bone marrow transplantation , 2009, Nature Medicine.

[141]  R. Porcher,et al.  Influence of bone marrow graft B lymphocyte subsets on outcome after HLA‐identical sibling transplants , 2009, British journal of haematology.

[142]  X. Li,et al.  Costimulatory pathways in transplantation: challenges and new developments , 2009, Immunological reviews.

[143]  F. Ginhoux,et al.  Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation , 2009, The Journal of experimental medicine.

[144]  C. Dinarello,et al.  Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-31 , 2009, The Journal of Immunology.

[145]  J. Ritz,et al.  Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[146]  K. Akashi,et al.  Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. , 2009, Blood.

[147]  M. Degli-Esposti,et al.  Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells1 , 2009, The Journal of Immunology.

[148]  G. Besra,et al.  Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration. , 2009, Blood.